EVMN — Evommune, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 2044725 ·
Last close
$13.67
Market Cap
$496.11M
52W High
$25.87
52W Low
$10.47
ADV30
520,879
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -34,895,000 | -32,246,000 | 301,947,000 | 60,034,000 | 24,361,000 |
| Mar 2026 | 0 | — | -23,954,000 | -21,674,000 | 322,455,000 | 48,318,000 | 17,900,000 |
| Dec 2025 | 0 | — | -29,716,000 | -28,273,000 | 224,946,000 | 44,063,000 | 19,380,000 |
| Sep 2025 | 10,000,000 | — | -13,328,000 | -12,475,000 | 84,544,000 | 26,818,000 | 267,681,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-74,153,000
Investing CF
$-200,872,000
Financing CF
$274,217,000
CapEx
$-370,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.37
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-275,009,000
Inventory
—
Receivables
—
ST Investments
$140,759,000
EBIT TTM
$-101,893,000
Pretax Income TTM
$-94,668,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,000,000
EBITDA
$-100,356,000
Free Cash Flow
$-39,127,752
Enterprise Value
$316,651,424
Total Cash
$200,792,992
Total Debt
$8,629,000
Shares Out
36,292,113
Trailing EPS
$-11.82
Book Value
$7.65
ROE
-52.1%
ROA
-32.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,000,000 | -81,071,000 | -68,870,000 | 224,946,000 | 19,380,000 | — | -76,441,000 |
| Dec 2024 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.36
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc. | $495.87M | $11.36 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $488.55M | $4.58 | — |
| QTTB | Q32 Bio Inc. | $487.03M | $16.36 | — |
| KMDA | KAMADA LTD | $486.36M | $8.43 | — |
| RZLT | Rezolute, Inc. | $482.42M | $5.01 | — |
News headlines (Yahoo Finance, 1h cache)
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-08-06 20:05 · Yahoo
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
2026-07-30 12:00 · Yahoo
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
2026-06-30 15:15 · Yahoo
Evommune terminates oral drug’s development in CSU
2026-06-29 15:28 · Yahoo
Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)
2026-06-29 14:16 · Yahoo
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
2026-06-29 12:30 · Yahoo
Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth
2026-05-11 12:05 · Yahoo
Evommune bucked biotech IPO drought and is focused on the long game
2026-04-07 08:00 · Yahoo
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
2026-06-24 14:31 · Yahoo
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says
2026-04-10 15:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.